Voyager Therapeutics Q3 EPS $(0.59) Misses $(0.58) Estimate, Sales $4.61M Beat $2.91M Estimate
Portfolio Pulse from bharat@benzinga.com
Voyager Therapeutics reported Q3 losses of $(0.59) per share, missing the analyst consensus estimate of $(0.58) by 1.72 percent. This is a 231.11 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $4.61 million, beating the analyst consensus estimate of $2.91 million by 58.56 percent. This is a 88.77 percent decrease over sales of $41.09 million the same period last year.
November 06, 2023 | 9:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Voyager Therapeutics reported lower than expected earnings and higher than expected sales for Q3. Both earnings and sales have significantly decreased compared to the same period last year.
The company's earnings missed estimates and decreased significantly compared to the same period last year, which could negatively impact the stock price. However, the sales beat estimates, which could have a positive effect. The overall impact is likely to be negative due to the significant decrease in both earnings and sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100